FTC: Patent Deals Need Not Involve Overt Payments to Be Anticompetitive

Generic Line
Patent settlements that involve a branded company’s commitment to not launch an authorized generic (AG) in competition with a generic company (no-AG agreements) are “without a doubt” anticompetitive pay-for-delay deals even though no cash payments are involved, the FTC says in an amicus brief.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00